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We describe the first case of failure of oral levofloxacin
treatment of community-acquired pneumonia caused by
Haemophilus influenzae. The strain showed cross-resist-
ance to fluoroquinolones and carried four mutations in
quinolone resistance–determining regions of DNA gyrase
and topoisomerase IV genes. 
Fluoroquinolones active against Streptococcus pneumo-niae and Haemophilus influenzae, such as lev-
ofloxacin, moxifloxacin, and gatifloxacin, are currently
recommended for the treatment of patients with communi-
ty-acquired pneumonia whose infection may be due to
strains resistant to β-lactam and macrolide antimicrobial
drugs (1–3). In Spain, both pathogens often display multi-
ple resistance (4,5). The failure of oral levofloxacin treat-
ment in four patients with pneumococcal pneumonia has
recently been reported (6).
We describe failure of treatment of H. influenzae pneu-
monia in a patient who died after several days of systemic
treatment with levofloxacin. The H. influenzae strain, iso-
lated from the blood and the respiratory tract of the patient,
was resistant to levofloxacin, ciprofloxacin, moxifloxacin,
and gatifloxacin and carried several mutations in the
quinolone resistance–determining regions (QRDR) of
DNA gyrase and topoisomerase IV genes. 
Case Report
On February 15, 2002, a 71-year-old woman was
admitted to Hospital de l’Esperit Sant, Santa Coloma de
Gramenet, Barcelona, with cough, low-grade fever, and
reported fatigue. A radiograph of her chest showed infil-
trates covering the right upper, middle, and lower lobes
and the left basal lobe. A systemic, antimicrobial treatment
of levofloxacin (500 mg/day) and teicoplanin (400
mg/day) was administered for severe community-acquired
pneumonia. (The patient was allergic to penicillin.) Three
months earlier, she had received erythromycin. In a second
visit, she was treated with inhaled salbutamol and gluco-
corticoids. In a third visit, 2 months before she became ill,
she received oral moxifloxacin for 5 days.
During her hospital stay, the patient’s clinical condition
worsened. Ventilation and perfusion scintiphotographs
with Tc99m, an echocardiograph, and a high resolution
thoracic scan were performed in an effort to identify anoth-
er illness or a possible nondrained focus; results were neg-
ative. After 7 hospital days of systemic levofloxacin thera-
py, her clinical condition had not improved. Two blood
cultures taken after an episode of fever with a temperature
of 38.5°C showed that H. influenzae was resistant to fluo-
roquinolones (strain 32602). Treatment was switched to
chloramphenicol (1 g/6 h), to which the strain was suscep-
tible. However, on the same day as the treatment change,
the patient was intubated during a severe episode of respi-
ratory impairment and transferred to the intensive care unit
of Hospital de l’Hospitalet, L’Hospitalet de Llobregat,
Barcelona. Fluoroquinolone resistance was confirmed with
blood cultures (strain 35102) and a bronchial aspirate
(strain 35202). Antimicrobial treatment was then switched
to aztreonam (1 g/8 h). The patient died 48 hours later.
The Study
Species identification, biotyping, and serotyping fol-
lowed recommended protocols (7), including capsule
genotyping of six capsular types (types a–f). Susceptibility
testing was performed by microdilution methods, follow-
ing the guidelines of the National Committee for Clinical
Laboratory Standards (8). β-lactamase activity was deter-
mined by the chromogenic cephalosporin test with nitro-
cephin as substrate. Quality control strains used were H.
influenzae ATCC 49247, H. influenzae ATCC 51907, and
Escherichia coli ATCC 25922. Determination of an even-
tual active efflux mechanism of fluoroquinolone resistance
was carried out by MIC determination in the presence and
absence of carbonyl cyanide 3-chlorophenyl (CCCP) and
reserpine in all three clinical strains (9).
The three test strains and four additional H. influenzae
biotype II isolates (obtained previously from blood and
respiratory specimens from the geographic area where the
patient lived) were examined by pulsed-field gel elec-
trophoresis (PFGE) after digestion of bacterial DNA with
SmaI (MBI Fermentas, Vilnius, Lithuania) and separation
of the fragments with the CHEF Mapper apparatus
(BioRad Laboratories, Hercules, CA) and were visually
compared (10). 
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Amplification and sequence analysis of the QRDRs of
gyrA, gyrB, parC, and parE was performed in the three
clinical test isolates and in the reference strain H. influen-







TAC-3′), and parE-r (5′-GAACAGGGCACAGAG-
TAGGGT-3′). Sequencing was done on both DNA strands
with the Big Dye Terminator Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA), according to the
manufacturer’s instructions. The products were resolved
and analyzed with an ABI PRISM 377 DNA sequencer
(Applied Biosystems). Nucleotide sequences were ana-
lyzed by using sequence analysis software (DNAstar, Inc.,
Madison, WI).
The three clinical isolates were identified as noncapsu-
lated H. influenzae biotype II. The PFGE yielded the same
pattern for each, unlike the marked diversity obtained with
the four other clinical isolates from the same geographic
area (Figure), and the same antimicrobial drug susceptibil-
ity testing results (Table). The results of DNA sequencing
of the QRDRs of the gyrA, parC, parE, and gyrB genes are
shown in the Table. All three strains presented identical
amino acid substitutions. They did not produce β-lacta-
mase and were fully susceptible to several β-lactam
antimicrobial drugs and chloramphenicol. MICs of addi-
tional antimicrobial drugs were penicillin, 0.25 µg/mL;
ampicillin, 0.12 µg/mL; amoxicillin-clavulanic acid,
0.12/0.06 µg/mL; cefuroxime, 0.12 µg/mL; cefotaxime,
0.03 µg/mL; aztreonam, 0.03 µg/mL; chloramphenicol,
0.12 µg/mL; erythromycin, 16 µg/mL; clarithromycin, 16
µg/mL; and azithromycin, 8.0 µg/mL. Quinolones, other
than those depicted in the Table, had the following activi-
ty levels: ofloxacin, 32.0 µg/mL; grepafloxacin, 32
µg/mL; clinafloxacin, 2.0 µg/mL. No changes in the MICs
of fluoroquinolones were observed either in the presence
or absence of CCCP or reserpine, suggesting that active
efflux did not contribute to fluoroquinolone resistance in
any of the isolates.
Conclusions
This study is the first description of a clinical case of a
fluoroquinolone-resistant H. influenzae pneumonia and
bacteremia, resulting in therapeutic failure and death after
systemic levofloxacin treatment. The causative strain was
present in cultures from the patient’s blood and bronchial
aspirate. This finding is consistent with the interpretation
of the initial chest x-rays, which indicated a clinical case of
severe community-acquired pneumonia. Similar cases of
community-acquired pneumococcal pneumonia treated
with levofloxacin have recently been reported (6). 
We have previously described the emergence of fluoro-
quinolone-resistant H. influenzae in the upper respiratory
tract of patients with chronic respiratory infections treated
with oral fluoroquinolones (7,12). However, in this patient
the only documented exposure to a fluoroquinolone was a
DISPATCHES
1476 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 9, No. 11, November 2003
Figure. Pulsed-field gel electrophoresis patterns of the three clini-
cal isolates of levofloxacin-resistant Haemophilus influenzae from
the case report (lanes 1 to 3) and four control cases of lev-
ofloxacin-susceptible H. influenzae biotype II strains isolated from
the same geographic area (lanes 4 to 7). Lane 1: strain 32602
(blood); lane 2: strain 35102 (blood); lane 3: strain 35202
(bronchial aspirate); lane 4: pleural fluid isolate; lane 5: blood iso-
late; lane 6: pleural fluid isolate. M, molecular markers.
Table. Fluoroquinolone susceptibility and amino acid changes in GyrA, ParC, GyrB, and ParE QRDR fragments of three Haemophilus 
influenzae strains compared with a fully fluoroquinolone-susceptible straina 
MIC (µg/mL) Amino acid at specified positions 
Strain no. CIP LEV MOXI GATI GyrA ParC ParE 
ATCC 51907 0.007 0.03 0.01 0.003 84 Ser  88 Asp 84 Ser 420 Asp 
32602, 35102, 35202 16 16 8 16 Leu  Asn Ile Asn 
aQRDR, quinolone resistance-determining regions; CIP, ciprofloxacin; LEV, levofloxacin; MOXI, moxifloxacin; GATI, gatifloxacin. Microdilution used for 
susceptibility testing (8). 
5-day treatment with moxifloxacin 2 months before the
pneumonia appeared. This case suggests that exposure to a
fluoroquinolone may contraindicate the use of another flu-
oroquinolone; however, this proposal may not be practical,
especially in a patient who is allergic to penicillin.
We have already established that amino acid substitu-
tions in the QRDRs of DNA gyrase and topoisomerase IV
accounted for the mechanism of fluoroquinolone resist-
ance in H. influenzae (12).The positions and the amino
acid substitutions found in GyrA and ParC in this study
were also present in the fluoroquinolone-resistant strains
previously studied by our group (12). We have also
described the Asp420Asn substitution (ParE) in another
strain that exhibited high resistance levels to ciprofloxacin
and other fluoroquinolones (13). However, the pattern of
QRDR mutations found in the clinical strains described in
this study is novel. 
Use of the “mutant prevention concentration” has been
proposed to discourage the selection of fluoroquinolone-
resistant mutants, since resistant mutants are selected
exclusively within a concentration range known as the
“mutant selection window” (14). This “window” may be
more easily attained with therapeutic regimes based on
oral and once-daily administered doses, as is the case for
moxifloxacin and levofloxacin. An important difference
between S. pneumoniae and H. influenzae is that the
MIC90’s for levofloxacin are 1.0-2.0 µg/mL and 0.03
µg/mL, respectively (3), a 30-fold difference. This sug-
gests that the events necessary to reach a similar level of
resistance in H. influenzae are more complex than they are
in S. pneumoniae.
The peak level of levofloxacin, 4 hours after a 500-mg
dose, is approximately 4.0 µg/mL (serum) and 11.0 µg/mL
(epithelial fluid) (3,15), which is clearly below the MIC of
16.0 µg/mL shown by these resistant strains. Where these
clinical H. influenzae strains originated is unknown.
Following the patient’s oral moxifloxacin treatment 2
months before hospital admission, the H. influenzae may
have become resistant to fluoroquinolones through a typi-
cal, step-by-step mutation process in the primary targets,
DNA gyrase and topoisomerase IV, by means of four muta-
tions in gyrA, parC, and parE, genes. The initial treatment
also may have resulted in the mutations in gyrA only, with
additional mutations occurring during the subsequent
treatment with levofloxacin.
The H. influenzae strain acquired several mutations in
the QRDRs and was cross-resistant to all members of a
group of assayed fluoroquinolones. We believe that this
case may represent an emerging clinical and microbiolog-
ic challenge, which may threaten the management of pneu-
monia and other infections. We recommend that blood cul-
tures taken from patients with community-acquired pneu-
monia be tested for fluoroquinolone resistance, particular-
ly when the patient has already been given these antimicro-
bial drugs.
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